| Avamere Rehabilitation At Fiesta Park | |
| 8820 Horizon Boulevard Ne, Albuquerque, New Mexico 87113 | |
| (505) 998-1551 | |
| Name | Avamere Rehabilitation At Fiesta Park |
|---|---|
| Location | 8820 Horizon Boulevard Ne, Albuquerque, New Mexico |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 85 |
| Occupancy Rate | 53.41% |
| Medicare ID (CCN) | 325123 |
| Legal Business Name | Albuquerque Operations Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1376044974 |
| Organization Name | OP OPERATIONS I, LLC |
| Doing Business As | NORTH KANSAS CITY HEALTH RETREAT |
| Address | 8820 Horizon Blvd Ne, Albuquerque, NM 87113 |
| Phone Number | 505-516-0940 |
News Archive
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
It's the time of year when backyards attract children, trails beckon hikers, and poison ivy attacks the unwary. This itch-causing plant pest, along with its cohorts poison oak and poison sumac, cause more common allergic reactions than any other source, said Renee Miller, R.N., a certified specialist in poison information at the Tennessee Poison Center at Vanderbilt University Medical Center.
TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.
› Verified 5 days ago
| NPI Number | 1518600949 |
| Organization Name | FIESTA PARK WELLNESS & REHABILITATION LLC |
| Address | 8820 Horizon Blvd Ne, Albuquerque, NM 87113 |
| Phone Number | 505-998-9868 |
News Archive
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
It's the time of year when backyards attract children, trails beckon hikers, and poison ivy attacks the unwary. This itch-causing plant pest, along with its cohorts poison oak and poison sumac, cause more common allergic reactions than any other source, said Renee Miller, R.N., a certified specialist in poison information at the Tennessee Poison Center at Vanderbilt University Medical Center.
TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.
› Verified 5 days ago
| NPI Number | 1619447554 |
| Organization Name | ALBUQUERQUE OPERATIONS LLC |
| Address | 8820 Horizon Blvd Ne # Na, Albuquerque, NM 87113 |
| Phone Number | 505-998-1551 |
News Archive
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
It's the time of year when backyards attract children, trails beckon hikers, and poison ivy attacks the unwary. This itch-causing plant pest, along with its cohorts poison oak and poison sumac, cause more common allergic reactions than any other source, said Renee Miller, R.N., a certified specialist in poison information at the Tennessee Poison Center at Vanderbilt University Medical Center.
TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.
› Verified 5 days ago
| NPI Number | 1649367830 |
| Organization Name | THI OF NEW MEXICO AT VALLE NORTE, LLC |
| Doing Business As | VALLE NORTE CARING CENTER |
| Address | 8820 Horizon Blvd Ne, Albuquerque, NM 87113 |
| Phone Number | 505-823-1885 |
News Archive
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
It's the time of year when backyards attract children, trails beckon hikers, and poison ivy attacks the unwary. This itch-causing plant pest, along with its cohorts poison oak and poison sumac, cause more common allergic reactions than any other source, said Renee Miller, R.N., a certified specialist in poison information at the Tennessee Poison Center at Vanderbilt University Medical Center.
TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.
› Verified 5 days ago
| NPI Number | 1790872976 |
| Organization Name | THI OF NEW MEXICO AT ALBUQUERQUE CARE CENTER, LLC |
| Doing Business As | ALBUQUERQUE CARE CENTER |
| Address | 239 Elm St Ne, Albuquerque, NM 87102 |
| Phone Number | 505-242-4116 |
News Archive
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
It's the time of year when backyards attract children, trails beckon hikers, and poison ivy attacks the unwary. This itch-causing plant pest, along with its cohorts poison oak and poison sumac, cause more common allergic reactions than any other source, said Renee Miller, R.N., a certified specialist in poison information at the Tennessee Poison Center at Vanderbilt University Medical Center.
TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.
› Verified 5 days ago
| NPI Number | 1962787812 |
| Organization Name | FIESTA PARK HEALTHCARE LLC |
| Doing Business As | THE MEDICAL RESORT AT FIESTA PARK |
| Address | 8820 Horizon Blvd Ne, Albuquerque, NM 87113 |
| Phone Number | 505-998-1551 |
News Archive
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
It's the time of year when backyards attract children, trails beckon hikers, and poison ivy attacks the unwary. This itch-causing plant pest, along with its cohorts poison oak and poison sumac, cause more common allergic reactions than any other source, said Renee Miller, R.N., a certified specialist in poison information at the Tennessee Poison Center at Vanderbilt University Medical Center.
TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
It's the time of year when backyards attract children, trails beckon hikers, and poison ivy attacks the unwary. This itch-causing plant pest, along with its cohorts poison oak and poison sumac, cause more common allergic reactions than any other source, said Renee Miller, R.N., a certified specialist in poison information at the Tennessee Poison Center at Vanderbilt University Medical Center.
TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $5000 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.16 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 0 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 26.92 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.13 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 10.2 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 18 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.68 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.11 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 15.16 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.04 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 17.86 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 83.61 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 59.62 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 80.64 | 82.93 |
News Archive
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
It's the time of year when backyards attract children, trails beckon hikers, and poison ivy attacks the unwary. This itch-causing plant pest, along with its cohorts poison oak and poison sumac, cause more common allergic reactions than any other source, said Renee Miller, R.N., a certified specialist in poison information at the Tennessee Poison Center at Vanderbilt University Medical Center.
TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S.
› Verified 5 days ago
Sandia Ridge Center Location: 2216 Lester Drive Ne, Albuquerque, New Mexico 87112 Phone: (505) 296-4808 | |
The Rehabilitation Center Of Albuquerque Location: 5900 Forest Hills Drive Ne, Albuquerque, New Mexico 87109 Phone: (505) 822-6000 | |
Las Palomas Center Location: 8100 Palomas Avenue Ne, Albuquerque, New Mexico 87109 Phone: (505) 821-4200 | |
Uptown Rehabilitation Center Location: 7900 Constitution Avenue Ne, Albuquerque, New Mexico 87110 Phone: (505) 296-5565 |